FGF19 and obesity due to melanocortin 4 receptor deficiency: Experimental administrations of FGF19 and transgenic FGF19 mice have shown decreased liver fat content, improved hepatic and serum lipid profiles, and resistance to high-fat diet-induced obesity [31-33].